Viral vectors are a critical component of cell and gene therapies, but process development and manufacturing of viral vectors are a major bottleneck in the industry. One of the current challenges is viral titer quantification, which can be low-throughput and high-cost, with poor robustness and reproducibility. Flow cytometry analysis of transduction efficiency is a popular alternative to traditional functional titer characterization by qPCR but can be prone to inconsistencies and misinterpretation. At Theragent Inc, we considered the pitfalls of flow cytometry and propose solutions to provide a functional viral vector titration with improved robustness and efficiency. Download the full white paper to read more about our process: https://lnkd.in/gQxSrp8J #FlowCytometry #ViralVectors #WhitePaper #CGT #CDMO #manufacturing #LVV
About us
Theragent Inc is a startup biotechnology company that specializes in developing and manufacturing novel personalized immunotherapies for cancer patients around the world. Our envisioned cGMP manufacturing facility is based in Southern California to support our local and global partners, including biotech companies, hospitals, academic centers, and research organizations.
- Website
-
http://www.theragent.com
External link for Theragent Inc
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Los Angeles
- Type
- Privately Held
- Founded
- 2019
- Specialties
- CDMO, Immunotherapy, Cell Therapy, and Biopharma
Locations
-
Primary
Los Angeles, US
Employees at Theragent Inc
-
Raymond Wu Ph.D.
Translating therapy
-
Weifeng "Frank" Zhang
Senior VP of Operations
-
Jeff Masten MBA
Transformative Biotech C-Suite Leader | 25+ Years in Pharma & Cell Therapy | Led $80M CDMO Startup | Global CMC Strategist | BOD for CellVax…
-
Shiva Gojgini
Analytical Development Manager, Theragent, Inc.
Updates
-
We are looking forward to the 9th Annual CAR-TCR Summit Series on Sept. 17-20! With a packed agenda ahead full of T-cell receptors, CAR-Ts, TILs, NKs, and Tregs, we're looking forward to meeting with folks to discuss how Theragent Inc's full-service CGMP facility with operational Pharma 4.0 can support the discovery, translation, development and manufacturing of these promising therapeutics. Use the One-on-One Partnering app to meet with Brian Newsom or Francis Nguyen to learn more about how Theragent can partner on your therapy at any stage. If you haven't registered for the CAR-TCR Summit Series, you can sign up now using our special discount code! See you in Boston! #CDMO #CART #Tregs #NKcells #TIL #manufacturing #CGT #celltherapy https://lnkd.in/dEFk7tAJ
-
At Theragent Inc, we constantly are researching and testing new methods to help deliver the therapeutics of tomorrow to patients in need of them today. Download our latest white paper to see how we are driving new methods to generate NK cells using a feeder-free platform with reduced risks. #NKcells #CGT #CDMO #whitepaper
Feeder-free Natural Killer (NK) cell expansion systems are a desirable choice for clinical applications due to reduced safety risks. However, historically lower expansion rates of these systems present a challenge to widespread clinical adoption and are a key reason why feeder-based expansion systems are still frequently used, despite safety and regulatory risks. Check out Theragent's latest research, led by Raymond Wu Ph.D., on an innovative NK cell therapy solution that can help overcome this barrier. https://lnkd.in/gYQj2mDJ #CAGT #NKCELL #THERAGENT
A Feeder-Free Platform For Generating Mature Natural Killer Cells
cellandgene.com
-
Theragent Inc reposted this
Feeder-free Natural Killer (NK) cell expansion systems are a desirable choice for clinical applications due to reduced safety risks. However, historically lower expansion rates of these systems present a challenge to widespread clinical adoption and are a key reason why feeder-based expansion systems are still frequently used, despite safety and regulatory risks. Check out Theragent's latest research, led by Raymond Wu Ph.D., on an innovative NK cell therapy solution that can help overcome this barrier. https://lnkd.in/gYQj2mDJ #CAGT #NKCELL #THERAGENT
A Feeder-Free Platform For Generating Mature Natural Killer Cells
cellandgene.com
-
NK cells have the natural ability to enhance therapeutic antibodies by triggering Antibody Dependent Cellular Cytotoxicity (ADCC), and data shows that NK cells don’t elicit side effects typically caused by T cell therapies. The traditional activation method uses feeder cells that mimic antigen presenting cells, typically made from cancer cells such as human leukemia cell lines, creating both safety and manufacturing variability concerns. To address these potential concerns, we explore efforts to activate and expand NK cells without the requirement of feeder cells. Download the full white paper to learn more about our approach: https://lnkd.in/gnifbcpM #whitepaper #NKCells #CGT #CDMO #manufacturing
White Paper Download: A Feeder-Free Platform for Generating Mature Natural Killer Cells
https://theragent.com
-
What's on your checklist for a CDMO? Do you know what to be looking out for when finding the right partner to develop your advanced therapeutic? Beyond capabilities, there are many factors to consider when building a relationship between CDMOs and sponsors. If you are a prospective client, read the full CDMO Checklist Series to see what we recommend keeping in mind to help guarantee a fruitful win-win relationship for everyone! https://lnkd.in/g-MhMsqG #CDMO #CDMOChecklist #CGT #manufacturing
A CDMO’s Checklist For Prospective Clients – Part One
https://theragent.com
-
Thank you to Perry Rearick and the entire team for hosting a great event! We are grateful for the opportunity to participate in Outsourced Pharma's Capacity Update back in May. If you're still looking for an opportunity to learn about our cell therapy development and manufacturing capabilities, be sure to check out Brian Newsom's presentation on demand! #CGT #CDMO #celltherapy #manufacturing
Chief Editor at Follow Your Buyer, Host of The Trailblazers, Moderator & Host for Outsourced Pharma Capacity Update, Clinical Leader Solutions Expo & Virtual Pharma Expo.
Brian Newsom from Theragent Inc speaks about their experienced team, use of state-of-the-art technology, and new facilities purpose-built for cell therapy development and manufacturing. If you missed the Outsourced Pharma Capacity Update Partner Week in May, you can see Theragent's entire presentation on demand along with all the CDMO presentations. And you can register for the next OPCU, July 22-24. https://lnkd.in/gjrh6vJQ Outsourced Pharma Life Science Connect Frank Luh, MD, MS, MHA Joseph Huang Weifeng "Frank" Zhang Michael Stadtlander Kendra Tetrick Angel Clark Jon Howland Cory Coleman Nathan Miller Tim Bretz Andreas Migias Kevin Morey Owen Takac Courtney Cornell Ray Sherman
-
If you’re developing T-cell receptors, CAR-Ts, TILs, NKs or Tregs, then we’ve got the ideal event for you to learn about the latest in discovery, translation, development and manufacturing of these promising therapeutics. Theragent Inc has partnered with CAR-TCR Summit Series in Boston, MA, so use our discount code to register so you can join us in September and save 20%! https://lnkd.in/gCq8gNcB #CGT #CDMO #celltherapy #manufacturing #CAR-T
-
#BIO2024 is just a few days away, and we can’t wait to connect with everyone at one of the largest biotech events of the year! 🎉 Come find Theragent Inc in the California Pavilion to learn more about how we’ve fully embraced Pharma 4.0 and what that means for your cell therapy development. You can also use the One-on-One Partnering app to schedule a meeting with Brian Newsom and Francis Nguyen before the start of the show! #BIO #CGT #CDMO #Manufacturing #CellTherapy #Pharma40
-
Are you getting ready to attend ISCT? So are we! Brian Newsom will be attending #ISCT in Vancouver next week. Schedule a meeting with Brian through the app to learn more about how Theragent, a full-service CGMP CDMO with operational Pharma 4.0, can help with your cell therapy development and manufacturing. #ISCT2024 #CGT #CDMO #manufacturing #celltherapy